Quest Diagnostics Incorporated - Asset Resilience Ratio
Quest Diagnostics Incorporated (DGX) has an Asset Resilience Ratio of 2.59% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check DGX strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Quest Diagnostics Incorporated's Asset Resilience Ratio has changed over time. See Quest Diagnostics Incorporated net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Quest Diagnostics Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Quest Diagnostics Incorporated market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $420.00 Million | 2.59% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $420.00 Million | 2.59% |
Asset Resilience Insights
- Limited Liquidity: Quest Diagnostics Incorporated maintains only 2.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Quest Diagnostics Incorporated Industry Peers by Asset Resilience Ratio
Compare Quest Diagnostics Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
SCOPE FLUIDICS SA ZY-10
F:S84 |
Diagnostics & Research | 32.55% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Quest Diagnostics Incorporated (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Quest Diagnostics Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.59% | $420.00 Million | $16.23 Billion | -0.81pp |
| 2024-12-31 | 3.40% | $549.00 Million | $16.15 Billion | -1.49pp |
| 2023-12-31 | 4.89% | $686.00 Million | $14.02 Billion | +2.44pp |
| 2022-12-31 | 2.45% | $315.00 Million | $12.84 Billion | -4.28pp |
| 2021-12-31 | 6.73% | $916.00 Million | $13.61 Billion | -5.24pp |
| 2020-12-31 | 11.97% | $1.68 Billion | $14.03 Billion | +2.69pp |
| 2019-12-31 | 9.28% | $1.19 Billion | $12.84 Billion | +8.05pp |
| 2018-12-31 | 1.23% | $135.00 Million | $11.00 Billion | -0.08pp |
| 2017-12-31 | 1.30% | $137.00 Million | $10.50 Billion | -2.25pp |
| 2016-12-31 | 3.55% | $359.00 Million | $10.10 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $9.96 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $9.88 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $8.95 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $9.28 Billion | -- |
| 2011-12-31 | 0.00% | $0.00 | $9.31 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $8.53 Billion | -- |
| 2009-12-31 | 0.00% | $0.00 | $8.56 Billion | -- |
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagn… Read more